2020
Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer.
Iwase T, Pusztai L, Blenman K, Li X, Seitz R, Nielsen T, Schweitzer B, Hout D, Bailey D, Zhang X, Shen Y, Ueno N. Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer. Journal Of Clinical Oncology 2020, 38: 3117-3117. DOI: 10.1200/jco.2020.38.15_suppl.3117.Peer-Reviewed Original ResearchPrimary triple-negative breast cancerTriple-negative breast cancerPathological complete responsePD-L1 IHCIM subtypesPredictive valueNeoadjuvant immunochemotherapyBreast cancerPhase I/II trialPretreatment core-needle biopsiesAntigen-presenting immune cellsPossible predictive markerImmune cell populationsImmune cell processesCore needle biopsyNegative predictive valuePositive predictive valueStrong predictive valuePositive likelihood ratioNegative likelihood ratioImmunomodulatory subtypeNeoadjuvant immunotherapyII trialLikelihood ratioComplete response
2019
Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC).
O'Meara T, Yaghoobi V, Blenman K, Pelekanou V, Silber A, Rimm D, Pusztai L. Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2019, 37: e14180-e14180. DOI: 10.1200/jco.2019.37.15_suppl.e14180.Peer-Reviewed Original ResearchTriple-negative breast cancerDisease-free survivalBetter disease-free survivalPD-L1 expressionCD68 expressionAA TNBCStromal PD-L1 expressionPD-L1 protein expressionCaucasian casesHigher TIL countsTumor immune microenvironmentImmune cell populationsHigh CD68 expressionHigh CD68Similar CD8Stromal TILsClinical characteristicsDiagnosis dateTIL countPD-L1Clinical outcomesPredictive factorsCD8 expressionClinical variablesImmune microenvironment
2014
Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients
Riess JW, Bhattacharya N, Blenman KR, Neal JW, Hwang G, Pultar P, Salcedo M, Engleman E, Lee PP, Malik R, Wakelee HA. Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. Immunopharmacology And Immunotoxicology 2014, 36: 182-186. PMID: 24494587, PMCID: PMC6464638, DOI: 10.3109/08923973.2013.864671.Peer-Reviewed Original ResearchConceptsMetastatic non-small cell lung cancer patientsNon-small cell lung cancer patientsCell lung cancer patientsTalactoferrin alfaLung cancer patientsImmune correlatesCancer patientsQuantitative immunohistochemistryNegative phase III trialsPhase II trial resultsImmune cell parametersTotal immune cellsTreatment tumor biopsiesPhase III trialsPre-treatment biopsiesInfiltration of tumorsDendritic cell maturationImmune cell populationsUnique recombinant formsMetastatic NSCLCIII trialsNSCLC patientsSystemic treatmentTrial closureCytokine release